Stockreport

Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Alto Neuroscience, Inc.  (ANRO) 
PDF – Topline data from two MDD trials expected in the first half of 2025: Phase 2b trial of ALTO-300 as an adjunctive treatment and Phase 2a trial of ALTO-203 in patients w [Read more]